ISSN : 2146-3123
E-ISSN : 2146-3131

Evaluation of the Efficacy of Aprepitant on the Prevention of Chemotherapy-Induced Nausea and Vomiting and Quality of Life with Functional Living Index Emesis
Görkem Aksu 1, Doğu Canoğlu 1, İlhan Dolaşık 2, Fatih Ensaroğlu 2, Selçuk Y. Şener 2, Faden H. Aydın 2, Süleyman Temiz 3, Kazım Uygun 3
1Department of Radiation Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
2Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
3Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
DOI : 10.5152/balkanmedj.2012.087
Pages : 64-67


Objective: Functional Living Index Emesis (FLIE) is developed to evaluate the relationship between emesis and it's effects on patient's daily life and is far more relevant to detect the effectiveness of antiemetic treatment compared with self-diary reports. In this study, the efficacy of oral neurokinin-1 antagonist aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life is evaluated with FLIE.

Study Design: Cross sectional study.

Material and Methods: Sixty patients with Non-Small Cell Lung Cancer (NSCLC) receiving a chemotherapy regimen consisting of Cisplatin and Docetaxel were evaluated. The patients were prospectively randomized to two groups before the first cycle of chemotherapy. Patients in Group A (31 patients) received 3 daily doses of aprepitant along with oral ondansetron and dexamethasone. The patients in group B (29 patients) received only ondansetron and dexamathasone. The efficacy of both regimens was evaluated by a modified Turkish version of FLIE scale consisting of 18 questions.

Results: The number of patients with complete response was 31 in the whole group. Of these 18 patients (58%) were in Group A (Aprepitant) and 13 patients in group B (42%). Median FLIE score in group A was 24.97 (±12.45) while it was 38.1 (±26.987) in group B and the difference was statistically significant (p=0.022). Total score >20 was seen in only 5 of 31 patients in aprepitant group (16%) showing the significant efficiency of aprepitant on quality of life, while in group B, 13 of 29 patients (44%) had total scores >20 (p=0.02).

Conclusion: Regarding these findings, it is certain to state that aprepitant in combination with other drugs optimizes protection against both nausea and vomiting compared to the prior standard of care, and must be recommended as first-line therapy for patients who are treated with moderately or highly emetogenic chemotherapy.

Keywords : Aprepitant, emezis, quality-of life, FLIE, chemotherapy

Viewed : 2685
Downloaded : 2152